tradmap

FDMT 4d Molecular Therapeutics, Inc.

$14.70 -1.64%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

4d Molecular Therapeutics, Inc. (FDMT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $812 million. Shares last traded at $14.70, 13.1% below their 52-week high. Over the past year the stock is up 126.9%. Net profit margin is -194.7%, below the peer median of 5.3%. Revenue grew 230194.6% year over year.

Market Cap
$812M
Shares Out
55.2M
EPS (TTM)
$-7.75
P/E Ratio
P/S Ratio
8.82
P/B Ratio
1.99
Dividend / Share
Dividend Yield
52-Week High
$16.91
52-Week Low
$6.10
Volume
43,378
Avg Vol (3m)
52,403.476

Performance

1W
-1.28%
1M
+42.86%
3M
+46.85%
6M
+70.53%
YTD
+100.68%
1Y
+126.85%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
58.86
SMA (50)
$12.43
SMA (200)
$10.09
Price vs SMA50
+18.22%
Price vs SMA200
+45.76%
ATR (14)
$1.04

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$92M
Net Income
$-179M
Gross Margin
Operating Margin
-214.2%
Net Margin
-194.7%
Return on Equity
-44.0%
Return on Assets
-36.4%
Current Ratio
8.03
Debt / Equity
0.05
Revenue Growth (YoY)
+230194.6%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-2.05 2026-08-13
Q1 2026 $-1.01 2026-05-07
FY 2025 $-2.42 2026-03-18
Q3 2025 $-2.85 2025-11-10
Q2 2026 $-1.84 2026-08-13
Q1 2026 $-0.86 2026-05-07

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

FDMT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
8.82 / 19.49 med
-55% discount
Net margin vs peers
-194.7% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.